Oncolytics Biotech R Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA Darmstadt Germany and Pfizer

Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer

Phase 2 BRACELET-1 study to evaluate Oncolytics' systemically delivered oncolytic virus, pelareorep, in combination with paclitaxel and anti-PD-L1 antibody avelumab SAN DIEGO, CA and CALGARY, AB / ...

More From BioPortfolio on "Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer"